BetterLife Pharma annual stock-based compensation
2018
2019
2020
2022
2023
2024
2025
2026
BetterLife Pharma Stock-Based Compensation Growth & History (BETRF)
BetterLife Pharma's stock-based compensation was $169,752 for fiscal 2026.
View full BetterLife Pharma company overviewBetterLife Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-01-31 | $169,752 | −$1.9M | −91.72% |
| 2025 | 2025-01-31 | $2.0M | $1.5M | +309.77% |
| 2024 | 2024-01-31 | $500,263 | −$450,802 | −47.40% |
| 2023 | 2023-01-31 | $951,065 | −$280,335 | −22.77% |
| 2022 | 2022-01-31 | $1.2M | — | — |
| 2020 | 2020-01-31 | $1.6M | $1.6M | +4961.16% |
| 2019 | 2019-01-31 | $31,567 | −$32,522 | −50.75% |
| 2018 | 2018-01-31 | $64,089 | — | — |
BetterLife Pharma quarterly stock-based compensation
Q1.19
Q1.20
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-04-30 | $152,932 | $88,788 | +138.42% |
| Q4 2026 | 2026-01-31 | $9,240 | — | — |
| Q3 2026 | 2025-10-31 | $57,679 | — | — |
| Q2 2026 | 2025-07-31 | $38,689 | — | — |
| Q1 2026 | 2025-04-30 | $64,144 | — | — |
| Q1 2020 | 2019-04-30 | $5,896 | −$29,002 | −83.11% |
| Q1 2019 | 2018-04-30 | $34,898 | — | — |
BetterLife Pharma stock-based compensation trends
Between the periods ended 2018-01-31 and 2026-01-31, BetterLife Pharma's stock-based compensation increased from $64,089 to $169,752, a change of $105,663. The latest reported quarter, Q1 2027, shows $152,932.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BetterLife Pharma source filings ↗